Latest Licensing Agreements News

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

archTIS has renewed 1,000 NC Protect licenses within the U.S. Department of Defense’s Microsoft DoD365 environment and secured an $8 million debt facility to accelerate its U.S. market expansion.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.

Emyria has secured its first Empax clinic in Victoria, marking a significant step in its multi-state expansion and validating its scalable, reimbursed national mental health platform.

Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.

Electro Optic Systems has inked a conditional US$80 million contract to supply a 100kW high energy laser weapon to a South Korean customer, marking its second major export order in this advanced defence technology.

TMK Energy has set new daily gas production records at its Gurvantes XXXV Coal Seam Gas Project, with November averages rising 18% over October and further gains in December. The company also completed its 2025 exploration program, confirming promising coal seam extensions.

Audeara Limited has secured its largest-ever Australian wholesale purchase order worth $560,000, driving year-to-date wholesale revenues to $1.75 million and matching full FY25 figures. The company is also expanding manufacturing into China, signaling growing international ambitions.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

AdAlta Limited has received a $0.78 million Research and Development Tax Incentive refund for FY2025, using part of it to repay a Radium Capital loan and strengthening its cash position as it nears a key licensing milestone.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Hexima Limited reveals plans to return capital to shareholders and restructure its board following the closure of its main clinical program and prolonged ASX trading suspension.